Monitor the pricing of this offering relative to the current $84.86/share price and the $71.76/share from the recent ATM offering. The success of the Phase 3 trials for rezpegaldesleukin will be the key determinant of long-term value, but near-term pressure from dilution is likely.
Price Chart
Executive Summary
Nektar Therapeutics is conducting a $250 million follow-on offering of common stock and pre-funded warrants, primarily to fund Phase 3 trials for rezpegaldesleukin in alopecia areata and atopic dermatitis. The offering follows positive Phase 2b extension data showing improved hair regrowth, but introduces significant shareholder dilution.
Key Facts
- $250 million follow-on offering of common stock and pre-funded warrants
- Proceeds to fund Phase 3 trials for rezpegaldesleukin in alopecia areata and atopic dermatitis
- Positive Phase 2b extension data shows improved SALT scores at 52 weeks
- No established market for pre-funded warrants, which are immediately exercisable
- Recent ATM offering raised $110 million at $71.76/share, with current cash balance of $741.7 million
Financial Impact
$250 million in gross proceeds from equity issuance, with significant dilution to existing shareholders
Risk Factors
- Significant shareholder dilution from the equity offering
- High cash burn rate for a clinical-stage biotech with no commercial products
- Pre-funded warrants create overhang with no established trading market
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001193125-26-164201 |
| Document: 0001193125-26-164201-index-headers.html | 0001193125-26-164201 |
| Document: 0001193125-26-164201-index.html | 0001193125-26-164201 |
| Document: 0001193125-26-164201.txt | 0001193125-26-164201 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 13, 2026 9w ago | Press Release | $73.02 $68.50 | ▼ −6.19% | ▼ −4.20% | $35.78 (−51.00%) |
Aug 9, 2026 10w ago | Institutional Cluster | $74.86 $75.44 | ▲ +0.77% | ▲ +1.69% | $35.78 (−52.20%) |
Aug 7, 2026 10w ago | Court Ruling | $76.48 $74.19 | ▼ −2.99% | ▼ −2.60% | $35.78 (−53.22%) |
Jul 28, 2026 11w ago | Press Release | $70.68 $73.77 | ▲ +4.37% | ▼ −0.65% | $35.78 (−49.38%) |
Jun 11, 2026 18w ago | Institutional Cluster | $59.21 $72.92 | ▲ +23.15% | ▲ +21.26% | $35.78 (−39.57%) |
Jun 11, 2026 18w ago | Institutional Cluster | $59.21 $72.92 | ▲ +23.15% | ▲ +21.26% | $35.78 (−39.57%) |
May 21, 2026 21w ago | Insider Cluster | $66.61 $65.25 | ▲ +2.04% | ▲ +0.63% | $35.78 (+46.28%) |
May 8, 2026 23w ago | 8-K | $78.72 $56.23 | ▲ +28.57% | ▲ +28.27% | $35.78 (+54.55%) |
May 7, 2026 23w ago | 8-K | $81.89 $57.32 | ▼ −30.00% | ▼ −30.03% | $35.78 (−56.31%) |
Apr 24, 2026 25w ago | DEFA14A | $86.74 $65.56 | ▼ −24.42% | ▼ −29.37% | $35.78 (−58.75%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access